Hospital Injectables Drug Market
Hospital injectables is a $624.5 Billion market in the US. We have focused on critical care, post-operative pain management, and hospital infections as our main therapeutic areas of development.
Our proprietary, innovative, Ready-To-Use branded injectable products will streamline getting these critical medications to patients.
Hospital Injectables Pipeline
NEVAKAR INJECTABLES HOSPITAL PRODUCTS ARE FOCUSED ON THREE MARKETS.
In the US, there are over 300M surgeries performed each year and 65% of patients reported having moderate to severe post-operative pain, despite the availability of approved analgesics.
There is a strong need for novel, non-opioid, multimodal therapy that can easily be administered in the postoperative period.
Nevakar Injectables’ novel approach should improve and simplify post-operative pain management.
Despite advances in the medication practices of hospital systems across the country, life-saving critical care medications continue to be admixed and administered sub-optimally.
These drugs contain molecules that degrade easily and require tedious preparation steps before they can be administered safely to patients; steps that lead to time unwanted delays when seconds matter and increase costs to fiscally-constrained hospitals.
Nevakar Injectables’ mission is to make existing drugs safer and easier to administer
Treatment of Hospital infections in the US account for about $10 billion in annual healthcare expenditures. Gram-positive infections, caused by organisms such as staphylococcus aureus, streptococcus pneumoniae, and enterococcus have an outer lipid cell membrane, and are a major cause of morbidity, mortality and cause complicated infections of many different tissues such as the skin, bloodstream, heart, lung, meninges, bone, and joints.
Nevakar Injectables has developed a proprietary and potentially safer and efficacious approach to overcome these life-threatening infections